DocWire News Editors

DocwireNews

A shorter one-month duration of treatment with dual-antiplatelet therapy (DAPT) followed by aspirin monotherapy was as effective as a six- to 12-month duration of treatment at preventing major cardiovascular (CV) outcomes and death in patients who just received a drug-eluting stent (DES), according to results of a study presented as part of a news briefing at the American Heart Association Scientific Sessions 2020.
“DAPT for one month followed by aspirin monotherapy was not inferior to 6 to 12 months of DAPT in terms of one-year outcomes among patients receiving DES,” said Myeong-Ki Hong, MD, PhD, of Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea. “The clinical implication is that discontinuing a P2Y12 inhibitor, rather than aspirin, in daily clinical practice may be associated with better patient compliance, lower costs, a lower risk of bleeding, and overall superior convenience and level of comfort for both patients and physicians.”
According to Dr. Hong, after DES implantation, DAPT with aspirin and a P2Y12 inhibitor is required to prevent ischemic events, such as stent thrombosis or myocardial infarction.
“However, as we know, prolonged dual antiplatelet therapy is costly and increases the likelihood of bleeding and patient noncompliance; thus, efforts have been made to shorten the duration of dual antiplatelet therapy,” Dr. Hong added.
The current recommendation is that duration of DAPT should be six to 12 months after stent placement. According to Dr. Hong, it is necessary to determine the appropriate minimal duration of DAPT followed by aspirin monotherapy.
Dr. Hong and colleagues conducted a non-inferiority trial to look at one-month DAPT followed by aspirin (n=1,507) compared with a six- to 12-month duration (n=1,513). The composite endpoint was cardiovascular events or major bleeding at one-year follow-up.
The primary endpoint was similar between the two arms, occurring in 5.9% of patients assigned the shorter duration compared with 6.5% of patients assigned the longer duration. There was an absolute difference of -0.7% (P&lt;0.001 for non-inferiority).
There were no significant differences in clinical outcomes between the two arms at one year. Stent thrombosis occurred in 0.7% of the one-month group and 0.8% of the six- to 12-month group. Major bleeding occurred in 1.7% of the one month group and 2.5% in the 6-12 month group.

A shorter one-month duration of treatment with dual-antiplatelet therapy (DAPT) followed by aspirin monotherapy was as effective as a six- to 12-month duration of treatment at preventing major cardiovascular (CV) outcomes and death in patients who just received a drug-eluting stent (DES), according to results of a study presented as part of a news briefing at the American Heart Association Scientific Sessions 2020.“DAPT for one month followed by aspirin monotherapy was not inferior to 6 to 12 months of DAPT in terms of one-year outcomes among patients receiving DES,” said Myeong-Ki Hong, MD, PhD, of Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea. “The clinical implication is that discontinuing a P2Y12 inhibitor, rather than aspirin, in daily clinical practice may be associated with better patient compliance, lower costs, a lower risk of bleeding, and overall superior convenience and level of comfort for both patients and physicians.”According to Dr. Hong, after DES implantation, DAPT with aspirin and a P2Y12 inhibitor is required to prevent ischemic events, such as stent thrombosis or myocardial infarction.“However, as we know, prolonged dual antiplatelet therapy is costly and increases the likelihood of bleeding and patient noncompliance; thus, efforts have been made to shorten the duration of dual antiplatelet therapy,” Dr. Hong added.The current recommendation is that duration of DAPT should be six to 12 months after stent placement. According to Dr. Hong, it is necessary to determine the appropriate minimal duration of DAPT followed by aspirin monotherapy.Dr. Hong and colleagues conducted a non-inferiority trial to look at one-month DAPT followed by aspirin (n=1,507) compared with a six- to 12-month duration (n=1,513). The composite endpoint was cardiovascular events or major bleeding at one-year follow-up.The primary endpoint was similar between the two arms, occurring in 5.9% of patients assigned the shorter duration compared with 6.5% of patients assigned the longer duration. There was an absolute difference of -0.7% (P&lt;0.001 for non-inferiority).There were no significant differences in clinical outcomes between the two arms at one year. Stent thrombosis occurred in 0.7% of the one-month group and 0.8% of the six- to 12-month group. Major bleeding occurred in 1.7% of the one month group and 2.5% in the 6-12 month group.

Jordana Jampel

Comparing Diets for IBS Relief: Mediterranean Versus Low-FODMAP

Gastroenterology

Anne Marie Morse, DO

Wearable Sleep Tech: Promise, Pitfalls, and Personalization

Sleep Disorders

Rebecca Shatsky, MD

ASCO 2025 Highlights: Dr. Rebecca Shatsky on Evolving Therapies in HR+ Breast Cancer

HR Breast Cancer

Latest News

Shorter Duration of DAPT Safe After Stent Placement

AHA Scientific Sessions 2020

A shorter one-month duration of treatment with dual-antiplatelet therapy (DAPT) followed by aspirin monotherapy was as effective as a six- to 12-month duration of treatment at ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Diabetes

Obesity

Metabolic Care Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe